Ryder Capital Delivers 33.53% Pre-Tax NTA Return and Confirms 12 Cents Dividend
Ryder Capital posted a robust 33.53% pre-tax NTA return for FY26, far outpacing market benchmarks, and announced a fully franked 12 cents per share dividend for FY27, underscoring confidence in its small-cap portfolio.
- 33.53% pre-tax NTA return for FY26
- 12.0 cents per share fully franked dividend confirmed for FY27
- Portfolio outperformed ASX benchmarks significantly
- Strong gains in core holdings like Macmahon and Lumos Diagnostics
- Portfolio remains undervalued with positive outlook
Exceptional FY26 Performance Outpaces Benchmarks
Ryder Capital Limited (ASX:RYD) reported a striking pre-tax net tangible asset (NTA) return of 33.53% for the year ending 30 June 2026, a figure that eclipses the S&P All Ordinaries Accumulation Index return of 5.70% and the S&P Small Ordinaries Accumulation Index return of 8.11%. This performance, achieved after all fees and expenses, pushed Ryder’s pre-tax NTA to $1.9803 per share, highlighting the strength of its investment strategy in small and micro-cap Australian equities.
Dividend Policy Reinforces Steady Income Commitment
Reflecting confidence in both past performance and future prospects, Ryder’s Board confirmed a minimum fully franked quarterly dividend of 3.0 cents per share for FY27, translating to an annual dividend of 12.0 cents per share. This dividend is underpinned by robust franking credits and retained profits, with coverage extending over five years. The dividend yield stands at a healthy 6.94% based on the current share price of $1.73, offering investors a compelling income stream alongside capital growth potential.
Portfolio Highlights Drive Outperformance
Ryder’s outperformance was fuelled by substantial gains in key holdings, including Macmahon Holdings (+213%), Lumos Diagnostics (+289%), Cuscal (+68%), Vitrafy Life Sciences (+101%), BCI Minerals (+16%), and SRG Global (+131%). These gains offset weaker returns from a few holdings such as Gentrack (-73%), Adore Beauty (-55%), and OFX Group (-26%), some of which the company anticipates will rebound in FY27. Notably, operational progress in unlisted investment Updater Technologies Inc. contributed positively, with a revaluation adding approximately 2.76% to June’s monthly return.
Active Management and Strategic Capital Recycling
The portfolio remains actively managed with a focus on realising profits and reinvesting in undervalued opportunities. Recent moves included opportunistic additions to OFX Group and Chrysos Corp, alongside a new position in soon-to-be-listed FDC Consolidated. Cash levels decreased to 6.89% from 10.16%, reflecting increased deployment into equities. The Board’s assessment is that the portfolio continues to trade below intrinsic value, setting the stage for further gains.
Key Sector Developments and Partnerships
Among sector-specific highlights, BCI Minerals attracted renewed interest following a broker report emphasizing project completion and undervaluation, alongside positive news in sodium ion battery technology with CATL’s large-scale launch potentially boosting demand for BCI’s salt products. Vitrafy Life Sciences successfully completed a $30 million capital raise after forming a strategic partnership with US blood collection organisation Vitalant, signaling growth potential in the life sciences segment.
Bottom Line?
Ryder Capital’s strong FY26 results and confirmed dividend policy reflect a confident stance on its small-cap portfolio’s undervaluation and growth potential, though selective underperformers warrant monitoring.
Questions in the middle?
- Will weaker holdings like Gentrack and Adore Beauty rebound in FY27 to sustain growth?
- How will Ryder’s active capital recycling strategy navigate potential market volatility?
- What impact will upcoming audited FY26 results and the Annual Report have on investor sentiment?
